Subscribe

medcelerator

Accelerating medical breakthroughs to patients

Understand new treatments and trials: who they may help, what the evidence shows, and how access differs by country.

Find by condition

Show treatments for

Health Canada/FDA ApprovedUnited States, Canada, Japan, China, Australia, Switzerland, European Union

Once-Weekly Insulin Shot for Adults with Type 2 Diabetes

Awiqli (insulin icodec / insulin icodec-abae) — once-weekly basal insulin

The first labelled once-weekly basal insulin. The United States (FDA, 26 Mar 2026) labels it only for adults with type 2 diabetes as an adjunct to diet and exercise for glycemic control. Health Canada (NOC 12 Mar 2024), the European Union (MA 17 May 2024), Switzerland (7 Mar 2024), Australia, and Japan label diabetes mellitus in adults — a broader line that includes type 1 with hypoglycemia caveats on those SmPCs / monographs. China’s NMPA line is type 2 only.

Breakthrough Brief

New treatments and trials, weekly. Every email has an unsubscribe link.

By subscribing, you request Breakthrough Brief emails. Privacy

Special series

Breaking Out: The Weight Class — Shots, Pills, and Organ Labels in 2026

Shots, pills, and organ labels in the 2026 weight class — Wegovy injection, Zepbound, the oral maze, and the process line that authorized is not funded. International by default. Zoom by country. Authorized is not funded.

Enter the seriesAll series

Treatment types

The next wave of treatment

All treatment types →

Gene Therapy

Cell Therapy

GLP-1

Glucagon-like peptide-1 (and dual GIP/GLP-1) medicines for diabetes, weight, and labelled organ-protection uses. Authorized is not funded.